In conclusion, these results collectively demonstrate that NAT10‐2023 exhibits strong therapeutic potential for liver cancer, effectively inhibiting tumor growth, reducing metastasis, suppressing hepatocarcinogenesis, preventing fibrosis, and preserving liver function across various preclinical models. The gene discussed is NAT10; the disease is neoplasm.